AnaptysBio's skin disease drug meets main goal in late-stage study (updated)

AnaptysBio

09/10/2023 13:27

(Adds details on study and disease in paragraphs 2-5)
       Oct 9 (Reuters) - AnaptysBio Inc  ANAB.O  said on Monday
its experimental drug to treat a type of rare skin disease met
the main goal in a late-stage study.
    The drug helped in clearing pus-filled blisters in patients
suffering with the condition, generalized pustular psoriasis, in
four weeks.
    The drug developer plans to submit marketing application for
the drug, imsidolimab, to the U.S. Food and Drug Administration
by the third quarter of 2024.
    The drug also demonstrated a favourable safety in patients
with no serious adverse events reported during the study, the
company said.
    Generalized Pustular Psoriasis (GPP) is a rare skin disease,
in which pus-filled blisters often cover large areas of the body
and typically cause fever, shivers, intense itching and joint
pain. 
    The company said it intends to license the drug and use the
potential proceeds to strengthen the development of its
autoimmune and inflammatory diseases portfolio.
    AnaptysBio's shares were placed on a trading halt.
    


 (Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj
Kalluvila)
 ((Khushi.Mandowara@thomsonreuters.com;))